ArticleAbdominal radiology (New York)2025
Ovarian masses suggested for MRI examination: assessment of deep learning models based on non-contrast-enhanced MRI sequences for predicting malignancy.
Article in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Performance of MRI protocols for diagnosis of benign and malignant ovarian tumors: a systematic review and meta-analysis.Abdominal radiology (New York) · 2026Review
- The use of MRI in the diagnosis of ovarian cancer.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe aims to assessed and compare four deep learning(DL) models using non-contrast-enhanced magnetic resonance imaging(MRI) to differentiate benign from malignant ovarian tumors, considering diagnostic efficacy and associated development costs.
methods526 patients (327 benign lesions vs 199 malignant lesions) who were recommended for MRI due to suspected ovarian masses, confirmed with histopathology, were included in this retrospective study. A training cohort (n=367) and a validation cohort (n=159) were constructed. Based on the images of T1-weighted imaging (T1WI), T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), we evaluated the diagnostic performance of four DL models (ConvNeXt, FBNet, GhostNet, ResNet50) in distinguishing between benign and malignant ovarian tumors. Two radiologists with varying levels of experience independently reviewed all original non-contrast-enhanced MR images from the validation cohort to determine if each case was benign or malignant. The area under the receiver operating characteristic curve (AUC), confusion matrices, accuracy, sensitivity, specificity, positive predictive value(PPV) and negative predictive value(NPV) were used to compare performance.
resultsThe study of 526 ovarian mass patients (ages 1-92) evaluated four DL models for predicting malignant tumors, with AUCs ranging from 0.8091 to 0.8572 and accuracy between 81.1% and 85.5%. An experienced radiologist achieved 86.2% accuracy, slightly surpassing the DL models, while a less experienced radiologist had 69.2% accuracy. Resnet50 had the highest sensitivity (78.3%) and NPV (87.3%), while ConvNeXt excelled in specificity and PPV (100%). GhostNet and FBNet are more parameter-efficient than other models.
conclusionThe four DL models effectively distinguished between benign and malignant ovarian tumors using non-contrast MRI. These models outperformed less experienced radiologists and were slightly less accurate than experienced ones. ResNet50 had the best predictive performance, while GhostNet was highly accurate with fewer parameters. Our study indicates that DL models based on non-contrast-enhanced MRI have the potential to assist in diagnosis.
Indexed as
Identifiers
40116887What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.